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Abstract
Background: This study is a comparative epigenetic evaluation of the methylation status of the DLC1
tumor suppressor gene in naturally-occurring canine lymphoma. Canine non-Hodgkin's lymphoma (NHL)
has been proposed to be a relevant preclinical model that occurs spontaneously and may share causative
factors with human NHL due to a shared home environment. The canine DLC1 mRNA sequence was
derived from normal tissue. Using lymphoid samples from 21 dogs with NHL and 7 normal dogs, the
methylation status of the promoter CpG island of the gene was defined for each sample using combined
bisulfite restriction analysis (COBRA), methylation-specific PCR (MSP), and bisulfite sequencing methods.
Relative gene expression was determined using real-time PCR.
Results: The mRNA sequence of canine DLC1 is highly similar to the human orthologue and contains all
protein functional groups, with 97% or greater similarity in functional regions. Hypermethylation of the 5'
and 3' flanking regions of the promoter was statistically significantly associated with the NHL phenotype,
but was not associated with silencing of expression or differences in survival.
Conclusion: The canine DLC1 is constructed highly similarly to the human gene, which has been shown
to be an important tumor suppressor in many forms of cancer. As in human NHL, the promoter CpG
island of DLC1 in canine NHL samples is abnormally hypermethylated, relative to normal lymphoid tissue.
This study confirms that hypermethylation occurs in canine cancers, further supporting the use of
companion dogs as comparative models of disease for evaluation of carcinogenesis, biomarker diagnosis,
and therapy.
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Background
Dogs with spontaneously arising lymphoma represent a
large animal model of naturally occurring non-Hodgkin's
lymphoma (NHL) in a species which shares the human
household environment and potential carcinogen expo-
sure[1]. Lymphoma in dogs is common and shares simi-
larities in cellular morphology and clinical behavior with
the human disease [2-7]. The indolent forms of human
NHL have a protracted course of disease that ultimately
leads to therapy resistance and death[8,9] Lymphoma in
dogs has a similar course of response to therapy followed
by terminal resistance. As such, the dog has been pro-
posed as a model for preclinical evaluation of novel diag-
nostics and therapeutics intended for human use[3,4]. To
date, only p53, p16, and retinoblastoma tumor suppres-
sor genes have been evaluated for mutation in canine
NHL [10-12]. No published examination of possible
hypermethylation of a tumor suppressor gene in a dog
with NHL exists.
The  DLC1  gene possesses tumor suppressor func-
tion[13,14]. The coded protein is a Rho-GTPase Activating
Protein (RhoGAP) that counteracts the feed forward sign-
aling of RhoA and Cdc42 among other Ras signaling pro-
teins[15]. Loss of this function results in unconstrained
growth signaling from the surface of the cell to the
nucleus, changes in cell mobility through increased
ROCK-mediated events, and signaling between the cell
and its extracellular environment[13,15-17]. The tumor
suppressor function has been confirmed by demonstrat-
ing that loss of DLC1 expression resulted in hepatocellular
carcinoma formation in a knockdown mouse model[14].
Transfection of DLC1 in vitro caused decreased prolifera-
tion and colony forming potential of non-small cell lung
carcinoma (NSCLC) cells and breast carcinoma cells [18-
20]. Stable transfection of DLC1 in a mouse model of met-
astatic NSCLC halted tumorigenicity of the cell line and
resulted in decreased invasiveness of the cells into normal
tissue[18]. Expression microarray analysis of transfected
cells revealed transcriptional upregulation of throm-
bospondin 2 (TSP2), a tumor growth inhibitor, acting
principally through counteracting angiogenesis[19].
The human DLC1 protein contains three recognized func-
tional domains: a sterile α motif (SAM), a RhoGAP, and a
steroidogenic acute regulatory-related lipid transfer
(START) domain domain[21]. The START and RhoGAP
domains are necessary for the tumor-suppressor function
of the protein[22]. Interaction with 14-3-3 protein bind-
ing in the linker area near the N-terminal SAM region
appears to regulate DLC1 function[23]. At points of focal
cellular adhesion, DLC1 interacts through a Src homology
2 (SH2) binding motif (Y422) with tensin family mem-
bers cten and tensin2 at the SH2 domain on each pro-
tein[21,24]. This interaction was confirmed by mutation
of the SH2 active regions of both DLC1 and cten, resulting
in a loss of both interaction and localization at the plasma
membrane[21]. DLC1 also interacts with tensin2 in cave-
olae, contributing to the organization of the local actin
cytoskeleton and inhibition of the formation of stress fib-
ers[24,25]. The interacting DLC1 and tensin2 suppress
activity of the serum response element (SRE), a Ras
cytoskeleton effector[25]. At focal adhesion sites, DLC1
function is modulated by binding of p120Ras-GAP[26].
Loss of such function could confer significant growth
advantages to preneoplastic or neoplastic cells, contribut-
ing to the initiation, promotion, or progression of cancer,
as well as metastasis. Indeed, DLC1 silencing has been
demonstrated to be a significant contributor to many
human cancers. This gene and its protein have not yet
been characterized in the dog.
The presence of a hypermethylated promoter region of the
DLC1  gene has been demonstrated in humans with
NHL[17,27]. Shi and colleagues examined NHL cell lines
and patient samples for hypermethylation of CpG islands
with differential methylation hybridization (DMH) using
a CpG island microarray[27]. The DLC1 gene was found
to be hypermethylated in all six NHL cell lines examined,
with concomitant silencing of transcription. In several
lines, expression could be upregulated by treatment with
a combination of a demethylating agent and a histone
deacetylase inhibitor. Seventy-five NHL patient samples
were examined for hypermethylation of several candidate
genes, including DLC1. Of these, 87% demonstrated
hypermethylation of DLC1[27]. Overall, expression of
mRNA for this gene was significantly downregulated in
tumor tissue compared to normal tissue[27]. Only
recently have epigenetic mechanisms begun to be exam-
ined in dogs[28]. Initial work by our group has identified
strong evidence that the tumor suppressor gene DLC1 is
frequently hypermethylated in canine NHL, as it is in
human NHL[27,29].
The purpose of this series of experiments was to sequence
the canine DLC1 gene and determine whether hypermeth-
ylation of the gene is present in canine lymphoma. No lit-
erature or databank information characterizes this gene in
dogs. While new, more precise prediction software has
identified a putative structure for the canine DLC1 gene,
no biological data confirms its existence or its expression
in canine tissue. The studies presented here define the
sequence of the mRNA, characterize the similarities and
differences of the structure of the dog and human pro-
moter regions of DLC1, report expression levels in the
normal lymphoid samples and canine NHL samples, and
identify DNA methylation patterns and their relationship
to the expression of the gene.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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Results
The construction of the canine DLC1 cDNA (GenBank
FJ602870) as determine by 5'RACE is presented in Figure
1. It is constructed highly similarly to the human DLC1,
(GenBank AF026219)[13]. The canine cDNA sequence
shares 88% identity with the human sequence. The pep-
tide sequences share 89% identity. All major human
exons are represented in the canine sequence. The SAM,
RhoGAP, and START domains are also present in the
canine sequence with extremely high homology of 97% or
higher. The SH2 interacting domain (hs Y442; cf Y450)
and surrounding sequence is preserved in the dog (data
not shown). The arginine finger (hs R677; cf R684) of the
RhoGAP is also preserved in the dog (Figure 1).
Conserved motif analysis of the promoter sequences
revealed strong homology between dog and human.
There is a particularly strong conservation of Sp1 binding
motifs. Of the canine Sp1 sites, 69% are common to
human and 68% of the human sites are common to dogs.
Furthermore, within the specific forms of the sites, inter-
action with pathway signaling is largely common between
the two, including jun, dihydrofolate reductase, and
gamma-globulin signaling pathways. Differences
observed include cyclooxygenase signaling Sp1 in dogs
and heat shock protein 70 signaling Sp1 in humans. Rela-
tive to human, the canine sequence has a higher density of
CpG dinucleotides. The dog Sp1 sites are also more
densely packed at the 5' end of the promoter region rela-
tive to the human sequence.
The conservation of non-Sp1 transcription factor binding
sites is less striking. Of the conserved elements, only 41%
are common to both the human and canine sequences.
Conserved elements common to both species include ras
and jun pathway binding sites.
Patient demographic data is presented in Table 1. The
mean and median ages of the dogs with NHL were 7.8 and
7 years, respectively (range: 5-13 y). The mean and
median weights of the dogs were 24.6 kg and 22.7 kg,
respectively (range: 5.6-48.4 kg). Nineteen dogs were
diagnosed with B-cell lymphoma and 2 with T-cell lym-
phoma.
The results of the combined bisulfite restriction analysis
(COBRA) are presented in Table 2. The BstuI cut-site,
located centrally in the amplicon (Figure 2) was methyl-
ated in seven of 21 cases, with no methylation detected by
COBRA in the seven normal samples (Figure 3). Methyla-
tion of this site was not significantly associated with the
lymphoma phenotype (P = 0.141). The TaqaI cut-site
demonstrated methylation in 19 of 21 cases, frequently
complete in its cutting. This site was also weakly positive
in two of seven normal samples (Figure 3). Methylation at
the TaqaI site was significantly associated with the lym-
phoma phenotype (P = 0.009). The HpyCh4IV cut-site
showed visual evidence of methylation in every case and
four of seven normal samples (Figure 3). By gel software
analysis, however, 11 of 21 cases and three of seven nor-
mals were deemed positive. Methylation of this site was
not significantly associated with the lymphoma pheno-
type (P = 1.00). At the 3' end of the CpG island, 17 of 21
case and no normal samples were positive for methylation
by methylation-specific PCR (MSP) (Figure 3). Methyla-
tion at this site was significantly associated with the lym-
phoma phenotype (P < 0.001). The relative ratios of the
methylated bands and total lane intensity are presented in
Table 2. Hypermethylation was not significantly associ-
ated with lymphoma classification or survival.
Bisulfite sequencing data is presented in Figure 4. Five
clones each from control dog 1 and lymphoma dogs 5, 12,
and 19 were sequenced. As predicted by the pattern of
COBRA results, methylation was present in the 5' region
of the sequence at a visibly greater density than at the 3' of
the amplicon. Density of methylation was the least in the
normal Dog 1, with sporadic methylation more promi-
nent at the 5' end near the edge of the CpG island. Density
was significantly different from normal for lymphoma
Dog 19 (P = 0.032). Dog 5 displayed slightly less methyl-
ation at the TaqaI cut-site than either dog 12 or 19. Dog
12 displayed the least methylation at the BstuI cut-site,
with dog 5 intermediate between 12 and 19. All dogs dis-
played near complete methylation of the HpyCh4IV cut-
site as suggested by the visual analysis of the gel, although
methylation was slightly less complete in the normal dog.
The small, diffuse nature of the band prevented adequate
digital analysis in 10 of the cases. The AP-2 transcription
factor binding site is located at the sixth CpG dinucle-
otide, and the ninth through fifteenth are included in Sp1
binding sites.
The relationship between age and relative methylation at
each of the assay sites was examined using linear regres-
sion analysis. The relationship identified at the TaqaI site
was positive (r = 0.394), but not significant (P = 0.086).
The calculated power of the analysis was also low (0.403).
This was the highest correlation identified. Normal sam-
ples were not included in this analysis, as they belong to a
separate class, and the effect of lymphoma could not be
separated from the effect of age.
Expression was variable in both normal and lymphoma
samples, ranging from 0 to 3.03 relative to the GAPDH
expression within the matching sample. Only for dog 21
was the expression undetectable, and this dog demon-
strated methylation only in the MSP assay. There was noBMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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Structure of the canine DLC1 gene based on sequencing results from mRNA isolated from normal spleen tissue Figure 1
Structure of the canine DLC1 gene based on sequencing results from mRNA isolated from normal spleen tis-
sue. The results have been deposited in GenBank with the accession number NM_001145071.1. The relative location of the 
protein translation start codon and functional groups in the mRNA are diagrammed, including sterile alpha motif 2 (SAM2), 
Rho GTPase Activating Protein motif (RhoGAP), and the lipid START motif. The location of each is described by the base 
number of the mRNA. The amino acid sequences for each functional group are depicted in parallel with the human sequence. 
The location of each peptide sequence is described by the residue number. The protein is 1083 amino acids long.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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statistically significant relationship between methylation
at any site and the expression of the gene in these NHL
samples (P = 0.423).
Discussion
Inactivation of the tumor suppressor gene DLC1 by dele-
tion has recently been shown to occur nearly as frequently
as p53 deletions in common human cancers[14]. Epige-
netic silencing of the gene has been identified in cell lines
and primary tumors of non-small cell lung, neuroectoder-
mal, breast, colon, prostate, gastric, renal, uterine, esopha-
geal, naspharyngeal, and rectal cancers, as well as
NHL[15,18,30-35]. To better characterize lymphoma in
dogs as a model for the human disease, we sequenced the
canine DLC1 gene and evaluated the effect of hypermeth-
ylation on its expression. Sequencing of the 5' region of
the cDNA was made difficult by the high GC content. The
sequence presented here was isolated from normal canine
spleen, and is highly similar to that reported by Yuan and
others, isolated from human liver tissue[13].
Both human and canine sequences originate immediately
downstream from a large CpG island, contain the same
number of exons, and share protein functional groups. A
gap is present in the canine genome build 2.0 in chromo-
some 16 from 39,504,330-39,505,008. A portion of the
fifth exon of the DLC1 sequence lies within this gap, fur-
ther revealing the sequence of the canine genome. The
similarities in the canine and human amino acid
sequences and in the transcription factors capable of bind-
ing to the control regions of these orthologs suggest highly
common functions between the two. The promoter anal-
ysis presented here is a significant expansion from that
previously reported[29]. Although specific pathway inter-
actions are impossible to predict simply by the presence of
conserved elements, the similarities conserved, and the
differences that have arisen, are striking between the
canine and human promoter elements of DLC1. The con-
servation of Sp1 binding sites between dog and human is
high. The canine Sp1 sites are collected slightly more 5'
and more densely relative to the human, with a less dense
distribution of sites throughout the first exon and first
intron region, which may have functional impact on
methylation of the region. These findings suggest signifi-
cant commonality of transcription control between dogs
and humans, with subtle alterations introduced during
the years of divergent evolution.
The extremely high GC content of this CpG island limited
bisulfite evaluation to the margins of the island. The
COBRA and MSP results demonstrate a pattern of greater
density of methylation in the 5' and 3' flanking regions of
the promoter of the canine gene with lower density of
methylation near the core of the promoter region where,
Table 1: Demographic data of dogs in the study
Patient # Sex Breed Age BW B/T Stage Survival Diagnosis
1 FS Am Co Sp 13 14.5 B IV 706 Lymphoma
2 FS Affenpinscher 12 5.6 T IV 14 DSLL
3 MC Mix 5 11.7 B IV 52* DLCL
4 FS Mix 11 30.4 B IV 104 DLCL
5 MC Engl Spring 6 22.7 B III 605 DLCL
6 MC Mix 8 22.7 B IV 238 DLCL
7 FS Mix 7 22.5 B IV 458 LBL
8 MC Lab 6 43.7 B III 448 DLCL
9 MC Staff Terr 10 34.8 B IV 6 FL II
10 MC Mix 12 28.1 B IV 754@ DLCL
11 FS Schnauzer 11 10 B N/A 231 Lymphoma
12 FS Welsh Corgi 7 17.7 B V 972@ DLCL
13 MC Blue Tick 7 34.1 B III 266 LBL
14 MC Collie 5 32.2 T II 97 Lymphoma
15 FS Engl Spring 5 25.7 B V 352 FL III
16 MC Rottweiler 5 36 B V 684 Burkitt
17 MC Am Co Sp 8 15.2 B IV 324 Lymphoma
18 MC Golden 5 48.4 B III 128 DLCL
19 FS Beagle 9 11.6 B V 140 DLCL
20 FS Mix 5 17.5 B V 427 DLCL
21 FS Golden 5 34.2 B IV 270 Lymphoma
Abbreviated breeds include American cocker spaniel (Am Co Sp), English springer spaniel (Engl Spring), Staffordshire terrier (Staff Terr), Blue tick 
hound (Blue Tick), Golden retriever (Golden) and mixed-breed dogs (Mix). Age is listed in years. Body weight is listed in kilograms. The 
immunophenotype (B/T) is listed. The stage is according to the World Health Organization staging standards. Survival is listed in days. Survival times 
marked with "@" to denote dogs alive at final analysis or lost to follow-up. Diagnosis is listed according to the Working Formulation where the 
tissue blocks could be retrieved or as lymphoma where they could not. Abbreviations for the diagnoses are as follows: DSLL, diffuse small 
lymphocytic lymphoma; DLCL, diffuse large cell lymphoma; LBL, lymphoblastic lymphoma; FL II, follicular lymphoma II; FL III, follicular lymphoma III.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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presumably, transcription is controlled. The greater
number and density of Sp1 binding sites, relative to the
human gene, may provide a boundary region, preventing
the spread of methylation into the core of the promoter,
even in neoplastic lymphocytes[36]. The HpyCh4IV cut
site, the first CpG in the bisulfite sequencing analysis, is
also the first CpG dinucleotide included in the island in
the Methprimer analysis. This CpG dinucleotide may
function as a genomic CpG, rather than as part of the
island, and be methylated in almost every animal. The
high rate of methylation in the bisulfite sequencing anal-
ysis supports this, as does the visual analysis of the gel
image. Only the TaqaI site and the MSP data were signifi-
cantly correlated with the neoplastic phenotype. Of these
two, MSP is likely the better discriminator because meth-
ylation was present only in the NHL samples. Methylation
at the BstuI site should continue to be evaluated in larger
trials, as no normal sample was hypermethylated at that
location on COBRA analysis.
The bisulfite sequencing results provide a visual represen-
tation of the likely control apparatus of this canine gene.
AP-2 does not appear to contribute significantly to the
expression of canine DLC1, as the binding site was uni-
formly methylated in two of the three lymphoma samples
and partially in the normal sample. It is possible that the
high density of Sp1, or another less frequent transcription
factor, overwhelms any contribution of AP-2, as well pro-
tects other transcription factors within the core of the pro-
moter region from hypermethylation. There is
methylation in only a small minority of the Sp1 binding
sites. This is in contrast to the methylation pattern identi-
fied in DLC1 in human prostate cancer in which the Sp1
sites are more heavily methylated, contributing to silenc-
ing[37]. An Sp1 boundary phenomenon has been
reported in the BRCA1  promoter of breast cancer
cells[38]. In vitro the Sp1 binding sites were shown to
serve as normal boundaries between the hypermethylated
and hypomethylated regions at the border of the gene
control region[38]. Furthermore, methylation of these
binding sites resulted in inhibition of binding by Sp1.
This boundary effect was abrogated by specific mutation
in a mouse model examining the Aprt gene[36]. In fact, no
relationship appears to exist in the samples studied
between the methylation status of the examined CpG
island regions and the expression of this gene. Expression
was present in all but one sample, and was highest in one
of the lymphoma samples. This is not surprising, given the
apparent protection of the majority of the core promoter
binding sites identified. Discordant methylation and
expression has been reported in the human gene hTERT
by several investigators [39-41]. A critical, hypomethyl-
ated region has been discovered around the transcription
start site (TSS) of the hTERT gene that allows transcription
in spite of heavy methylation upstream[42]. It is likely
that the canine DLC1 gene is similar, in that methylation
not present in normal tissue can be readily demonstrated
in the CpG island of canine NHL samples, but the core of
the promoter appears unmethylated, allowing transcrip-
tion to occur. Overall, expression of the gene is low in
both node tissue and circulating lymphocytes, as found in
humans by Shi and others[27]. The highest mRNA expres-
sion in this series was in lymphoma dog 17, but protein
expression was not evaluated.
Of the 21 cases of lymphoma in this study, two were of T-
cell immunophenotype. Unlike in our previously
reported study, hypermethylation was identified in both
cases. Methylation has been reported in T-cell lymphoid
neoplasia. DLC1 was hypermethylated in three of six
human patients with T-cell ALL[43].
Genomic hypomethylation and accumulation of CpG
island hypermethylation has been associated with
increasing age in humans[44]. This may be contributory
to the development of cancer as individuals age. A similar
phenomenon of accumulated CpG island hypermethyla-
tion has not been demonstrated in dogs. In this series of
lymphoma samples, there was no statistically significant
association between age and the degree of hypermethyla-
CpG island and promoter regions of canine DLC1 with meth- ylation assay sites identified Figure 2
CpG island and promoter regions of canine DLC1 
with methylation assay sites identified. The amplicon 
for the COBRA analyses spans from nucleotide 4 through 
190. Restriction enzyme cut sites are marked in bold and 
underlined in this section. The Sp1 binding sites are in plain 
text and underlined. The BLAST comparison with the human 
promoter identified the region from nucleotide 100 to 675. 
The Promoterscan prediction identified the region that is 
italicized and underlined as likely to be the promoter, the 
final 38 nucleotides of which are within the first exon. The 
MSP primer sites are bolded at the 3' end of the sequence. 5' 
RACE determined the transcription start site to be at base 
466, Chromosome 16:39,535,666.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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tion. This phenomenon should be studied further in nor-
mal and diseased populations of dogs with sufficient
sample size to answer this question.
Analysis of hypermethylation by site identified no rela-
tionship between Working Formulation classification or
survival in these dogs. This is not surprising, as the hyper-
methylation had no effect on expression of canine DLC1.
Hypermethylation has been shown to be a frequent find-
ing in all of the forms of human NHL, with differences
occurring primarily in degree of hypermethylation and
gene sets affected [45-47]. The present cases were only
classified by Working Formulation criteria after the fact. If
comparative studies are to bear fruit on a mechanistic
level, disciplined classification must become the norm for
veterinary pathologists and clear prognostic significance
must be attached to the different classifications. Develop-
ment of diagnostic technology for flow-cytometry, anti-
gen-receptor gene rearrangement, and, now, epigenetic
alterations of cells will define the points of origin of
canine NHL in B-cell biology that have already been
defined in human NHL[5,48]. Only with this information
will the comparative model be complete.
Conclusion
The results of this study further characterize the similari-
ties and differences between the human and canine DLC1
gene. The cDNA sequences of canine and human DLC1
are highly similar. The promoter regions of both human
and canine DLC1 have important similarities in content
of methylation sensitive transcription factors. Signifi-
cantly, the density of Sp1 sites in dogs is more numerous
and more concentrated at the 5' end of the promoter,
potentially making the canine CpG island more resistant
to hypermethylation. DLC1 is not silenced in canine NHL,
but the statistically significant relationship with the malig-
nant phenotype suggests that hypermethylation may be
used as a biomarker for neoplasia in abnormal lymphoid
populations. The clear association between hypermethyl-
ation and the malignant phenotype, taken with previously
published data demonstrating global hypomethyla-
tion,[28]. demonstrate that methylation patterns are
altered in canine forms of NHL in a similar manner to
human NHL. Current research in the author's laboratory
using high-throughput technology will begin to establish
the patterns of hypermethylation associated with specific
forms of lymphoma in dogs, and further define the com-
parative framework of NHL etiology, pathobiology, and
therapy between dogs and humans.
Methods
In Silico methods
A region of the canine genome corresponding to the
sequence surrounding the promoter region of the human
DLC1  gene (NM_006094) was identified as previously
described[29]. This region of DNA, located on chromo-
Composite representation of original gels for COBRA and MSP results Figure 3
Composite representation of original gels for COBRA and MSP results. Control animals are listed C1-C7. Cases are 
listed 1-21. Positive methylation controls are in the far right lane. Molecular makers are in the far left lane. Depicted are the 
COBRA results with digestion using BstuI, TaqaI, and HpyCh4IV. Methylation specific PCR results are depicted in the fourth 
row for the methylated primers and the fifth row for the unmethylated primers. All faint bands in the initial gels were con-
firmed in repeated assays.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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some 16 from 39,535,425 to 39,536,000 was considered
to contain the promoter sequence for development of the
subsequent studies.
A list of 7660 putative transcription factor motifs was
obtained from the SigScan database of the Bioinformatics
and Molecular Analysis Section of the Center for Informa-
tion Technology, National Institutes of Health. http://
www-bimas.cit.nih.gov/. Using the regular expressions
pattern matching function in MATLAB® version R2007a
http://www.mathworks.com/, these motifs were com-
pared with the canine and human DLC1 DNA sequences
and the start and stop sites were recorded for all perfect
matches. This resulted in 83 and 87 matched transcription
factor motifs for the canine and human sequences, respec-
tively. Of these, 10 canine and 14 human motifs represent
consensus motifs that could potentially represent differ-
ent specific transcription factor binding sites. There were
60 canine and 63 human motifs that were unique. The
locations of CpG dinucleotides were determined in a sim-
ilar fashion.
The sequence of canine DLC1  was translated using an
online Open Reading Frame Finder http://
www.ncbi.nlm.nih.gov/gorf/gorf.html. The sequences
were compared to the human DLC1 sequence available in
Gen-Bank using ClustalW http://www.ebi.ac.uk/clustalw/
index.html, an online alignment program[49]. Protein
functional group analysis was performed using an online
analysis program http://www.ebi.ac.uk/Tools/InterProS
can/[50].
Patient samples
The case samples were collected from dogs presenting to
the University of Missouri-Columbia Veterinary Medical
Teaching Hospital meeting the ethical standards of, and in
compliance with, IACUC requirements. Samples were
obtained by lymphadenectomy or Tru-Cut needle biopsy.
Samples were divided in two portions, placed in RNALater
(Ambion, Inc., Austin, TX), and stored immediately at -
80°C for later processing. The majority of the dogs in the
study underwent complete staging, including CBC,
plasma chemistry profile, bone marrow cytology, thoracic
Table 2: Results of COBRA and MSP methylation analysis and real time expression analysis
Dog B or T Cell Rel Intensity Meth 
at HpyCh4IV
Rel Intensity Meth 
at TaqA
Rel Intensity Meth 
at BstuI
Meth:Unmeth 
Ratio for MSP
Relative Expression
C1 Normal 0.0461 0 0 0 0.3618
C2 Normal 0 0 0 0 N/A
C3 Normal 0 0 0 0 0.0103
C4 Normal 0 0 0 0 N/A
C5 Normal 0 0 0 0 N/A
C6 Normal 0.142 0.1148 0 0 0.0175
C7 Normal 0.1234 0.0573 0 0 0.0248
1 B 0 1 0 0.2666 0.0686
2 T 0.1961 1 0 0.0661 0.0992
3 B 0 1 0.2625 0 0.0752
4 B 0.1501 0.7505 0 0.9251 0.0164
5 B 0.1616 0.6651 0.4209 0.4932 0.1984
6 B 0.1821 0.7968 0 0.2628 0.0034
7 B 0.1407 0.1093 0.1042 0.3039 0.0260
8 B 0.1345 0.4357 0.2742 0.3431 0.2078
9 B 0 1 0.2481 0.4366 0.1575
10 B 0.1794 1 0.3558 0.1679 0.0655
11 B 0 0.2191 0 0.5008 0.2127
12 B 0 1 0 0.17993 0.0412
13 B 0 1 0 0 0.0884
14 T 0.1428 0.0655 0 0 0.0508
15 B 0 0 0 0.3781 0.0171
16 B 0.0351 0.4653 0 0.0614 0.1063
17 B 0 1 0 0.1700 3.0314
18 B 0.116 1 0 0.1543 0.1895
19 B 0.1654 1 0.4372 0.1366 0.2806
20 B 0 1 0 0 0.1403
21 B 0 0 0 0.1355 0.0000
Totals 11/21 19/21 7/21 17/21
P value for lymphoma 1.00 0.009 0.141 <0.001
There are seven control and 21 lymphoma samples. COBRA results are described as relative intensity of the methylated band out of all bands in the 
lane. The MSP results are described as a ratio between the methylated and unmethylated primer sets. Because these primer sets use different 
conditions for amplification, the ratio cannot be directly interpreted as a proportion of methylated DNA, but as a number relative to the other 
samples. Samples marked N/A were unavailable for the particular analysis.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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radiographs, abdominal ultrasound, and biopsy for defin-
itive diagnosis and immunophenotyping. Staging was not
required for inclusion. The normal lymphocytes used for
this study were from laboratory dogs used for a concurrent
protocol[51], blood samples of healthy volunteer dogs, or
node samples harvested immediately after euthanasia of
donated animals without lymphoma. Peripheral blood
mononuclear cells were isolated over a ficoll-hypaque
(Sigma-Aldrich, St. Louis, MO) gradient and preserved at
-80°C until analysis. All available samples were reviewed
by a single pathologist (LMB) to assign a Working Formu-
lation diagnosis.
DNA and RNA preparation
Sample collection and preparation: Samples were divided
into two aliquots immediately after thawing in an ice
bath. DNA and RNA were harvested using Qiagen DNeasy
Tissue and RNeasy according to the provided protocols
(Qiagen, Inc. USA. Valencia, CA). Briefly, for RNA the tis-
sue was stabilized in RNAlater reagent to arrest RNase
activity. Samples were homogenized and lysed, DNA
sheared, and ethanol added. The solution was centrifuged
in a proprietary spin column to bind the total RNA. The
RNA was washed three times and, finally, eluted in RNase-
free water. DNA was extracted using the Qiagen DNeasy
Tissue kit (Qiagen, Inc. USA. Valencia, CA), and then
bisulfite treated using the Zymo Research EZ DNA Meth-
ylation Gold kit (Zymo Research Corporation, Orange,
CA). DNA from normal canine lymph nodes was treated
with SssI and SAMe to methylate all CpG dinucleotides
prior to bisulfite treatment in the sequence and serve as a
positive control.
Sequencing of cDNA
A spleen sample was removed from RNA later, ground in
liquid Nitrogen using a precooled mortar and pestle and
RNA was extracted using the RiboPure RNA extraction Kit
(Ambion, Austin, TX, USA) following the manufacturer's
specifications. The frozen powder was mixed immediately
with 1 mL TRI buffer (to make 5% W/V homogenate) con-
taining guanidinium thiocyanate. The homogenate was
transferred into RNase free 1.5 microcentrifuge tubes
(supplied in the kit) and quickly homogenized by vortex-
ing at maximum speed. The homogenate was then mixed
well by vortexing at maximum speed with 200 μL of chlo-
roform solution, incubated for 5 minutes at room temper-
ature, and centrifuged at 12,000 g for 30 seconds. The
aqueous phase (containing the RNA) was recovered and
mixed with 200 μL of 100% ethanol and applied to a glass
fiber filter. The RNA attached to the spin column was
washed twice with 500 μL of wash solution to remove
residual contaminants. Purified RNA was eluted from the
column in 100 μL Elution Buffer
Genomic DNA contaminant was eliminated by treatment
with rDNase I using the DNA-free kit (Ambion, Austin,
TX, USA). Total RNA (about 10 ug) was treated with
rDNase I consisting of 1 μL (2 units) rDNase I and 5 μL of
10× DNase I buffer. The reaction mixture was incubated in
a thermocycler at 37°C for 30 minutes then 5 μL of inac-
tivation reagent was added to terminate the reaction and
precipitate the rDNase. The mix was centrifuged at 10,000
g for 1.5 minutes and the RNA was transferred to a new
RNase and DNase free microcentrifuge tube. The RNA was
stored at -80°C until use.
The Ambion FirstChoice RLM-RACE (rapid amplification
of cDNA ends) (Ambion, Inc. Austin Texas) kit was used
to isolate the full length mRNA of the canine homolog of
DLC1 and perform 5' and 3' RACE. Briefly, total RNA was
treated with calf intestinal phosphatase to remove free 5'
phosphates from rRNA, fragmented mRNA, tRNA, and
DNA fragments. The 5' cap was removed with tobacco
Bisulfite sequencing results for normal dog 1, and dogs 5, 12,  and 19 with NHL Figure 4
Bisulfite sequencing results for normal dog 1, and 
dogs 5, 12, and 19 with NHL. The corresponding DNA 
sequence is above with each CpG dinucleotide marked in 
bold. Open circles denote unmethylated CpG dinucleotides 
and black are methylated. Five clones for each dog were sub-
mitted for sequencing. Note the relatively lower methylation 
density for the normal dog. The high frequency of methyla-
tion at the HpyCh4IV cut-site in all dogs, including the nor-
mal dog, suggests that this CpG behaves as a genomic CpG 
dinucleotide and is routinely methylated. Note the minimal 
methylation in the right half each set of clones where the Sp1 
sites reside.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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acid pyrophosphatase and a 45 base RNA adaptor was
added to the complete mRNA. random primed reverse
transcription reaction and nested PCR was used to
amplify the remainder of the 5' end. A similar procedure
was employed on the 3' end of the full length mRNA by
placing a 3' adaptor and repeating the random-primed
reverse transcription and nested PCR. Exonic primers that
overlapped by a minimum of 50 bases were designed
according to Ambion recommendation to amplify the
regions of the mRNA between the 5' and 3' amplified seg-
ments. The PCR product was enzymatically purified with
Exo-SapIt (Amersham, USA). PCR products were incu-
bated for 30 minutes at 37°C and the reaction was termi-
nated by incubation at 80°C for 15 minutes. (Amersham,
USA). PCR product were further purified with Zymo
Clean and Concentrator kit (Zymo Research Corporation,
Orange, CA) and eluted in 10 μL of HyPure water. Clean
PCR product was sequenced by cycle sequencing using
big-dye terminator. The reaction was carried out in a 10 μL
reaction containing 4 μL big-dye, 4 μL PCR, and 2 μL (3.2
pmol) primer. The mixture was cycled as follows: initial
denaturation at 96°C for 2 minutes, and 36 cycles of
96°C for 10 seconds, 50°C for 10 seconds, and 60°C for
4 minutes.
COBRA and MSP
The MethPrimer http://www.urogene.org/methprimer/
index1.html website was used to locate a primer region at
the 5' end of the CpG island to serve as the left primer[52].
Because the sequence contains a single CpG dinucleotide,
a second primer was designed to be complementary to a
TpG sequence at the same location. The right primer was
constructed 187 bp 3' to the first primer pairs, and con-
tains a single CpG dinucleotide as well, necessitating
design of TpG complementary primer as well. The product
size of these primers is 187 bp and contains one BstuI cut-
site yielding fragments of 116 bp and 71 bp, one TaqaI cut
site yielding fragments of 128 bp and 59 bp, and one
HpyCh4IV cut site yielding fragments of 160 and 27 bp.
The primers used for COBRA were (5' to 3'): forward, TAT-
AGTTTTAGGCGGTGTTTTGG and TATAGTTTTAGGTGGT
GTTTTGG and reverse, CCCAAAA TCCAACTCAAA ATT-
TACG and CCCAAAATCCAACTCAAAATTTACA. PCR was
performed at an annealing temperature of 60°C for 60 s,
an extension temperature of 72°C for 60 s, and a melting
temperature of 95°C for 60 s, repeating for 36 cycles. The
PCR product was purified with the Zymo Clean and Con-
centrator kit (Zymo Research Corporation, Orange, CA)
and eluted in 20 μL of HyPure water. For BstuI, 10 μL of
PCR product was added to 2.5 μL of Buffer 2, 1 μL of BstuI,
and 11.5 μL of HyPure water, and incubated at 60°C for 4
h. For TaqaI, 8 μL of PCR product was added to 2.0 μL of
Buffer 3, 1 μL of 10× bovine serum albumin, 1.5 μL of
TaqaI, and 7.5 μL of HyPure water, and incubated at 65°C
for 4 h. For HpyCh4IV, 8 μL of PCR product was added to
2.0 μL of Buffer 3, 1.5 μL of HpyCh4IV, and 8.5 μL of
HyPure water, and incubated at 37°C for 4 h. Controls
were bisulfite-treated DNA from normal lymphocytes
(negative) and bisulfite-treated SssI-treated DNA from
normal lymphocytes (positive). The PCR products were
run on a 1.5% agarose gel with ethidium bromide for vis-
ualization. MSP was performed as previously described
for this gene[29]. The primers used were: unmethylated
forward TGGTTTTAAGTTTAGTGGTTAGTGG; unmethyl-
ated reverse CCTTATCAAACCAATACCTATCATT; methyl-
ated forward GCGGTTTT AA GTTTAGTGGTTAGC;
methylated reverse CCTTATCAAACCGATACCTATCGT.
Results were analyzed using a gel documentation and
analysis system (Kodak, Rochester, NY). Proportion of
methylation for COBRA samples was calculated as the
intensity of the cut bands divided by the total intensity of
all bands in the lane. For MSP, a ratio of the intensity of
the methylated band to the unmethylated band was calcu-
lated.
Bisulfite sequencing
The PCR product of 5' COBRA primer set from three cases
and a normal dog was amplified, purified with the Qiagen
Clean and Concentrator kit (Qiagen, Inc. USA. Valencia,
CA) and eluted in 10 μL of HyPure water. Using the Invit-
rogen TA Cloning kit (Invitrogen Corporation, Carlsbad,
CA), the product was transfected into competent cells pro-
vided for transformation[29]. Single colonies of trans-
formed cells were selected and grown overnight in
enrichment broth with ampicillin. Plasmid DNA was
extracted using the Qiagen miniprep kit (Qiagen, Inc.
USA. Valencia, CA), and the presence of an insert, indicat-
ing a transformed cell, detected by PCR. Five clones of
each purified plasmid DNA were submitted with universal
primers where they were sequenced by the DNA Core
using a standard dideoxynucleotide sequencing tech-
nique. CpG dinucleotides within the sequences were
mapped and labeled as methylated if cytosine remained
unconverted, and unmethylated if a thymidine was in a
cytosine position.
Expression analysis
Primers were designed that reside in two adjacent exons,
spanning an intron, near the 3' end of the mRNA. Reverse-
transcriptase PCR was used to create a cDNA copy of the
mRNA. This cDNA copy was amplified in tandem with
GAPDH cDNA to yield relative copy numbers in SYBR-
Green Real-Time PCR. Primer sequences were as follows:
GAPDH forward GTGACTTCAACAGTGACACC; GAPDH
reverse CCTTGGAGGCCATGTAGACC; DLC1 forward
CTCACCTACATGTGCAGAGC; DLC1 reverse ACAACT-
TCAGCTGCACACAG. This was performed in five normal
dog samples, as a control population, and all NHL sam-
ples. Assays were run in triplicate to avoid inter-assay var-
iability. Data were evaluated using the ΔΔCt method.BMC Genetics 2009, 10:73 http://www.biomedcentral.com/1471-2156/10/73
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Statistical analysis
The relationship between degree of methylation and level
of expression and degree of methylation and age were
evaluated using a linear correlation model. Methylation
density of each NHL sample was compared to expression
of the mRNA relative to normal lymphoid tissue using a
Mann-Whitney rank sum test. Association between meth-
ylation at each restriction enzyme or MSP site and the
neoplastic phenotype or lymphoma subtype results was
examined using the Fisher's Exact Test. Differences in sur-
vival were calculated for dogs receiving a CHOP chemo-
therapy protocol which did or did not have methylation
at each restriction site and MSP analysis using the Kaplan
Meier Log-Rank Analysis. Significance was set at P = 0.05.
List of abbreviations
DLC1: Deleted in Liver Cancer 1; COBRA: combined
bisulfite restriction analysis; MSP: methylation-specific
PCR; NHL: non-Hodgkin's lymphoma; NSCLC: non-
small cell lung carcinoma; RhoGAP: Rho-GTPase Activat-
ing Protein; SAM: sterile α motif; SRE: serum response ele-
ment; START: steroidogenic acute regulatory-related lipid
transfer; TSP2: thrombospondin 2.
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